ChemTrak AccuMeter cholesterol test receives CLIA "waived" status.
This article was originally published in The Gray Sheet
Executive Summary
CHEMTRAK ACCUMETER CHOLESTEROL TEST MOVED TO CLIA "WAIVED" CATEGORY, the Sunnyvale, California-based company announced March 20. The reclassification decision by the Centers for Disease Control and Prevention clears the way for ChemTrak to market the diagnostic test to "more than 45,000 sites in physician offices, clinics and wellness programs...registered to perform waived testing only" under the Clinical Laboratory Improvement Amendments of 1988, the company said.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.